[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,944,728
  • Shares Outstanding, K 206,075
  • Annual Sales, $ 2,090 M
  • Annual Income, $ 424,880 K
  • EBIT $ 351 M
  • EBITDA $ 663 M
  • 60-Month Beta 0.64
  • Price/Sales 3.22
  • Price/Cash Flow 9.58
  • Price/Book 2.02

Options Overview Details

View History
  • Implied Volatility 47.38% (+0.57%)
  • Historical Volatility 42.45%
  • IV Percentile 72%
  • IV Rank 59.51%
  • IV High 65.79% on 03/13/26
  • IV Low 20.32% on 08/21/25
  • Expected Move (DTE 2) 1.91 (5.85%)
  • Put/Call Vol Ratio 3.75
  • Today's Volume 6,375
  • Volume Avg (30-Day) 1,856
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 70,984
  • Open Int (30-Day) 69,825
  • Expected Range 30.81 to 34.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.61
  • Number of Estimates 5
  • High Estimate $0.62
  • Low Estimate $0.60
  • Prior Year $0.63
  • Growth Rate Est. (year over year) -3.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.53 +0.52%
on 05/13/26
42.33 -22.75%
on 04/14/26
-9.21 (-21.98%)
since 04/13/26
3-Month
32.53 +0.52%
on 05/13/26
49.86 -34.42%
on 02/27/26
-17.71 (-35.13%)
since 02/13/26
52-Week
32.53 +0.52%
on 05/13/26
57.81 -43.44%
on 01/20/26
-11.63 (-26.23%)
since 05/13/25

Most Recent Stories

More News
QGEN Investor Alert: Levi & Korsinsky Investigates Qiagen (QGEN) for Potential Securities Fraud

Qiagen's forward-looking non-GAAP guidance lacked required GAAP reconciliations under SEC Regulation S-K Item 10(e) -- institutional investors who relied on these figures for portfolio allocation decisions...

QGEN : 32.70 (-2.97%)
QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company...

QGEN : 32.70 (-2.97%)
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting

Co-founder and former CEO Dr. Metin Colpan to become Honorary Chairman of the Supervisory Board after deciding not to stand for re-election ...

QGEN : 32.70 (-2.97%)
Lost Money on Qiagen N.V. (QGEN)? Contact Levi & Korsinsky to Protect Your Rights

New York, New York--(Newsfile Corp. - May 11, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. (NYSE: QGEN) ("Qiagen N.V.")  concerning potential violations...

QGEN : 32.70 (-2.97%)
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing

Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow ...

QGEN : 32.70 (-2.97%)
Levi & Korsinsky Investigates Qiagen N.V. (QGEN) Over Potential Securities Fraud Allegations

New York, New York--(Newsfile Corp. - May 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.") (NYSE: QGEN) concerning potential violations...

QGEN : 32.70 (-2.97%)
QIAGEN Reports Full Results for Q1 2026

Q1 2026 results in line with pre-announcement: Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates...

QGEN : 32.70 (-2.97%)
Qiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)

Qiagen projected a low single digit rate first-quarter QuantiFERON growth rate on February 5, 2026. Actual Q1 2026 volumes showed a 5% decline

QGEN : 32.70 (-2.97%)
Qiagen's Immigration Testing Problem: Temporary Reset or Canary in the Diagnostics Coal Mine

Barchart Research What to Expect from QGEN Earnings QGEN Generated May 5, 2026 Current Price $34.00 EPS Estimate $$0.54 Consensus Rating Moderate Buy Average Move 1.75% Qiagen's Immigration Testing Problem:...

QGEN : 32.70 (-2.97%)
Ongoing Investigation into Qiagen N.V. (QGEN): Contact Levi & Korsinsky About Potential Fraud

New York, New York--(Newsfile Corp. - April 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. ("Qiagen N.V.") (NYSE: QGEN) concerning potential violations...

QGEN : 32.70 (-2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed...

See More

Key Turning Points

3rd Resistance Point 34.75
2nd Resistance Point 34.37
1st Resistance Point 34.03
Last Price 32.70
1st Support Level 33.32
2nd Support Level 32.94
3rd Support Level 32.60

See More

52-Week High 57.81
Fibonacci 61.8% 48.16
Fibonacci 50% 45.17
Fibonacci 38.2% 42.19
Last Price 32.70
52-Week Low 32.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.